TY  - GEN
AU  - Garcia Campelo, Maria Rosario
AU  - Arriola, Edurne
AU  - Campos Balea, Begona
AU  - Lopez-Brea, Marta
AU  - Fuentes-Pradera, Jose
AU  - de Castro Carpeno, Javier
AU  - Aguado, Carlos
AU  - Perez Parente, Diego
AU  - de Oro Pulido, Fidel
AU  - Ruiz-Gracia, Pedro
AU  - Rodriguez-Abreu, Delvys
PY  - 2021
DO  - 10.3390/jcm10194583
UR  - https://hdl.handle.net/10668/27155
T2  - Journal of clinical medicine
AB  - This network meta-analysis (NMA) evaluates the safety of first-line programmed death-ligand 1 (PD-L1) inhibitor monotherapy in advanced NSCLC patients compared to platinum-based chemotherapy. We also compared the risk of adverse events (AEs) according...
LA  - en
PB  - Mdpi
KW  - non-small cell lung cancer
KW  - network meta-analysis
KW  - immunotherapy
KW  - first-line treatment
KW  - PD-L1 inhibitors
KW  - safety
KW  - Pd-1/pd-l1 inhibitors
KW  - Open-label
KW  - Chemotherapy
KW  - Pembrolizumab
KW  - Efficacy
KW  - Therapy
KW  - Tolerability
KW  - Multicenter
KW  - Expression
KW  - Nivolumab
TI  - PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis
TY  - review
VL  - 10
ER  -